Results 231 to 240 of about 301,002 (287)

A review of hepatitis B vaccination

Expert Opinion on Drug Safety, 2003
Hepatitis B is one of the most important infectious causes of acute and chronic liver disease both in the US and worldwide. In order to combat the life-threatening effects of hepatitis B infection, recombinant hepatitis B vaccines have been developed.
Arthur C. Zahalsky, David A. Geier, Mark R. Geier   +2 more
openaire   +3 more sources

Hepatitis b vaccination [PDF]

Current Hepatitis Reports, 2006
Hepatitis B virus (HBV)infection is a major cause of chronic hepatitis and cirrhosis,with an estimated 350 million people worldwide infected with the virus.Despite continuing advances in antiviral therapy,a cure for chronic HBV infection is considered an elusive goal.Thus,primary prevention by immunization with HBV vaccines remains the most effective ...
Henry C. Bodenheimer, Albert D. Min, Aaron Walsh   +2 more
openaire   +1 more source

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.

New England Journal of Medicine, 1986
To study the duration of antibody persistence and protection provided by the hepatitis B vaccine, we followed 773 homosexual men for five years after completion of vaccination.
S. Hadler, D. Francis, J. Maynard, S. Thompson, F. Judson, D. Echenberg, D. Ostrow, P. O'Malley, K. Penley, N. Altman, E. Braff, G. F. Shipman, P. Coleman, E. Mandel   +13 more
semanticscholar   +1 more source

Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine.

Molecular Pharmaceutics, 2011
Porous poly(L-lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) nanoparticles were tested for pulmonary delivery of hepatitis B vaccine.
Chandan Thomas, A. Rawat, L. Hope-weeks, F. Ahsan   +3 more
semanticscholar   +1 more source

Hepatitis B and A vaccines [PDF]

, 1989
Hepatitis has been recognized as a serious disease throughout recorded history. Outbreaks of jaundice came to be recognized over time as potentially infectious in nature. The confirmation of a viral aetiology to certain forms of hepatitis was established in the early 1940s in studies in human volunteers to whom hepatitis could be transmitted by a non ...
P. J. Provost, R. W. Ellis
openaire   +1 more source

Hepatitis B Vaccine [PDF]

, 1988
The first results of active immunization against hepatitis B in humans were reported a little over 10 years ago (Maupas et al., 1976). Since then, several serum-derived hepatitis B (HB) vaccines have been proved safe, highly immunogenic and efficacious in various populations at risk (Stevens et al., 1984).
F. Tron, A. Godefroy, Soulié Jc, F. Dubois, C. Louq, Brossard Y, A. Goudeau, J. Klein, J. Huchet   +8 more
openaire   +1 more source

Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy.

New England Journal of Medicine, 1984
We evaluated the immunogenicity and efficacy of hepatitis B vaccine (Heptavax-B) in a randomized, double-blind, placebo-controlled trial involving 1311 patients receiving hemodialysis in the United States. After three doses of vaccine (40 micrograms each)
C. Stevens, H. Alter, P. Taylor, E. Zang, E. Harley, W. Szmuness   +5 more
semanticscholar   +1 more source

Hepatitis B Vaccines [PDF]

, 1999
Hepatitis B virus (HBV) chronically infects 200–300 million people worldwide. The resulting acute and chronic disease that results from contact with these individuals or their blood is a leading cause of liver disease, including hepatocellular carcinoma, and mortality. In fact, HBV is second only to smoking as a cause of human cancers (1).
openaire   +1 more source

Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection.

New England Journal of Medicine, 1982
We evaluated the efficacy of hepatitis B vaccine (Heptavax-B) containing only the ad subtype in a randomized, placebo-controlled, double-blind trial among 865 staff members of 43 hemodialysis units in the United States. Surface antibody developed in 92.6
W. Szmuness, C. Stevens, E. Harley, E. Zang, H. Alter, P. Taylor, Anita De Vera, George T. S. Chen, A. Kellner   +8 more
semanticscholar   +1 more source

Immunogenicity of Hepatitis B Vaccines

JAMA: The Journal of the American Medical Association, 1994
To the Editor. —Vaccination using a full course of three doses of HBV leads to the development of protective antibody to anti-HBs response in 85% to 95% of all vaccinees. A small proportion of vaccinees, 1 however, fail to develop anti-HBs titers of greater than 10 mIU/mL, the minimal titer considered to be protective.
Jean Pierre Barthez, Jacques Germanaud
openaire   +3 more sources